Marc Martinell, PhD
Co-Founder & Chief Executive Officer
Marc obtained a PhD in Chemistry from the University of Barcelona. He has broad experience in drug discovery and biotechnology through his participation at companies such as Crystax Pharmaceuticals and Oryzon Genomics where he managed several research projects and led the team in charge of target selection, structural biology, computational chemistry and hit ID through a fragment-based approach. At Oryzon, Marc actively contributed to the identification of the first-in-class inhibitors for the epigenetic target LSD1 currently in clinical studies and licensed to Roche. Marc is co-author of several patents and publications, and besides his activities in the technological field always had an entrepreneurial calling.
Uwe Meya, MD PhD
Chief Medical Officer
Uwe is a neurologist and psychiatrist. He received his medical degree as well as his doctorate in psychiatry from the University of Aachen (Germany). He is a member of the European College of Neuropsychopharmacology as well as the International Parkinson and Movement Disorder Society and is a founding member of the International College of Geriatric Psychoneuropharmacology. He has over 30 years of experience in pharmaceutical research and development, with a special focus on central nervous system (CNS) and particulary neurodegenerative disorders, having worked at Schering, Knoll, Novartis, F.Hoffmann-La Roche, Biotie Therapies, and Lupin. He has expertise in all aspects of drug development from first-in-man trials to regulatory filing.
Xavier Barril, PhD
Scientific Founder, Inventor SEE-Tx technology
Xavier is a recognized expert in the field of computational chemistry and drug discovery, and prior to his incorporation to Universitat de Barcelona as ICREA professor, he had developed his career at Vernalis (Cambridge, UK) as Senior Investigator. Among other discoveries, Xavier co-discovered the Hsp90 inhibitors that Vernalis licensed to Novartis and which are currently in clinical trials. Xavier has co-authored more than 40 publications, including journals, books, reviews and patents, and is the inventor of the innovative technology that Minoryx is using to identify new pharmacological chaperones.
Jordi Petit, MBA
Graduate in Business Administration and Master in Business Administration (MBA) by ESADE Management School (Barcelona) and Master Community of European Management Schools (CEMS) by the Ecole Hautes Etudes Commerciales, HEC (Paris). His professional experience began in 1989 as CFO of Betne SA, publishing company, and as a founding partner and CFO of BPMO Edigroup SL. After working in 1992 in Bull Europe (Paris) in the Management Control area, he joined KPMG where he worked in Auditing and in Corporate Finance from 1994 to 1996. Afterwards he joined Acordis Acrylic Fibers, the first two years as Assistant to the Financial & Management Controller, becoming Controller in 1998. In 2000 he joined La Caixa, initially Caixa Holding, SA as Head of Controlling and Corporate Development for the business sector, and later as an Investment Director in Caixa Capital Risc, SGECR SA (venture capital firm of “la Caixa”) until 2007. From 2007 until 2011 he was CFO of Oryzon Genomics, SA. one of the leading Spanish biotechnology companies. Additionally, from September 2000 until June 2003 he combined his professional career with teaching experience as Professor of the Management Control course at the Faculty of Business Administration (ADE), IQS (Barcelona).
Pilar Pizcueta, PhD
Director of Biology
Pilar holds a PhD in Pharmacy from the Universitat de Barcelona. Supported by a Fulbright Postdoctoral Fellowship she worked at Harvard Medical School and later at Duke’s University, Durham (USA). Upon returning to Spain in 1995, she became an independent researcher at the Fundació Clínic- IDIBAPS in Barcelona and later on she moved to the pharmaceutical industry at Almirall as Head of the In Vivo Target Validation Unit in charge of generating and characterizing experimental models of diseases. She became program leader in Drug Discovery, supervising projects related to autoimmune diseases. During this period two drug candidates were forwarded to development and one of them has now entered in clinical trials. Afterwards she moved to CNIO as Head of In Vivo Target Validation from 2009 to 2012.
Sílvia Pascual, MSc
Director of Clinical Operations
Sílvia is a Pharmacist from the Universitat de Barcelona and after graduating she studied a Master of Science at King’s College, University of London. She has developed a broad experience in Clinical Development, pharmacovigilance and Regulatory Affairs at different companies such as GSK, Grifols and Almirall. In these companies, Sílvia managed several clinical research projects in different therapeutics indications, mainly in haematology, immunology, respiratory and dermatology. Some of these development programs obtained EMA and FDA approval to be marketed in both EU and US.
Richard Roberts, PhD
Director of Drug Disovery
Richard obtained a degree in Natural Sciences and a PhD in Organic Chemistry from the University of Cambridge. He then carried out a postdoc at Imperial College, London, ultimately leading the TeknoMed industrial collaboration for chemical library methodology. After a brief spell as an agrochemical Team Leader at Syngenta, UK, he moved to Almirall in Barcelona in 2002. His main focus has been as a Medicinal Chemist for several disease target classes for oral, inhaled or topical administration. He has also been involved in a range of other activities, from library synthesis, innovation platforms, compound logistics and managing major collaborations. Since 2008 he has been a program leader in Drug Discovery, supervising projects related to asthma, cough and pruritus..